Amgen Inc. $AMGN Position Boosted by Bath Savings Trust Co

Bath Savings Trust Co grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 2,509.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 23,147 shares of the medical research company’s stock after buying an additional 22,260 shares during the period. Amgen accounts for 1.0% of Bath Savings Trust Co’s portfolio, making the stock its 27th biggest position. Bath Savings Trust Co’s holdings in Amgen were worth $9,757,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares in the last quarter. Bank of America Corp DE bought a new position in Amgen in the 2nd quarter worth $1,831,903,000. Wellington Management Group LLP lifted its position in shares of Amgen by 1,102.7% in the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after purchasing an additional 2,514,254 shares during the period. BlackRock Inc. lifted its position in shares of Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares during the period. Finally, Corient Private Wealth LP bought a new stake in shares of Amgen during the 2nd quarter valued at about $187,401,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the topic of several research analyst reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of Amgen in a research report on Monday. Citigroup lifted their price objective on Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Sanford C. Bernstein upped their target price on Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th. Piper Sandler increased their target price on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Finally, Oppenheimer restated an “outperform” rating on shares of Amgen in a research note on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $385.79.

Amgen Stock Up 2.6%

NASDAQ AMGN traded up $10.48 during trading hours on Wednesday, reaching $413.08. 2,236,544 shares of the company’s stock traded hands, compared to its average volume of 2,758,837. Amgen Inc. has a 52-week low of $288.00 and a 52-week high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The firm has a 50-day simple moving average of $411.44 and a 200 day simple moving average of $371.01. The firm has a market cap of $223.32 billion, a PE ratio of 25.67, a PEG ratio of 2.91 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter in the prior year, the company earned $6.02 earnings per share. The business’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts anticipate that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. Amgen’s dividend payout ratio is presently 62.65%.

Insider Buying and Selling

In related news, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by corporate insiders.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported results from a clinical trial involving a treatment for Sjögren’s disease. The update appears to have supported the stock by providing investors with additional visibility into the company’s immunology pipeline. Amgen announces Sjogren’s trial results
• Positive Sentiment: Amgen participated in Arboretum LifeSciences’ $30 million Series A financing. The investment could give Amgen access to AI-driven genetic testing and molecular-data capabilities that may improve precision-medicine decisions and the design of genomically targeted clinical trials. Amgen backs Arboretum LifeSciences Series A
• Positive Sentiment: Amgen’s AMG 513 obesity study reached Phase 1 completion. While early-stage completion does not establish efficacy, the program adds another potential growth opportunity as the company competes in the weight-loss drug market. Amgen AMG 513 obesity trial update
• Neutral Sentiment: Cantor Fitzgerald maintained a Neutral rating, while another report cited a Neutral rating with a $400 price target. These views suggest analysts see limited near-term upside after the recent advance. Cantor Fitzgerald maintains Neutral rating
• Neutral Sentiment: A former Amgen commercial leader joined Entera Bio, a move relevant to Entera rather than Amgen and unlikely to materially affect AMGN’s fundamentals. Former Amgen leader joins Entera
• Negative Sentiment: Morgan Stanley lowered its price target to $359 while maintaining an Equal Weight rating, and Truist raised its target to $380 but kept a Hold rating. Both targets remain below the current share price, signaling valuation concerns and potential downside. Morgan Stanley lowers Amgen price target Truist raises Amgen price target

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.